Drug Trial News

RSS

NCI, Tau Therapeutics open enrollment in mibefradil Phase Ib glioma trial

Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that it has opened enrollment for a Phase Ib clinical trial with the National Cancer Institute's Adult Brain Tumor Consortium (ABTC) using the company's first product candidate mibefradil.

1 Jun 2012

Oncothyreon commences PX-866 and vemurafenib Phase 1/2 combination trial for melanoma

Oncothyreon Inc. today announced the initiation of a Phase 1/2 trial of PX-866 in combination with vemurafenib.

1 Jun 2012

RXi’s RXI-109 IND receives FDA clearance to proceed into clinical trials

RXi Pharmaceuticals Corporation today announced that it has received clearance for its investigational new drug application (IND) from the U.S. Food and Drug Administration (FDA) to initiate clinical trials with RXI-109, a self-delivering RNAi compound that selectively targets Connective Tissue Growth Factor.

1 Jun 2012

Omeros commences planned PK substudy in Phase 3 clinical program of OMS302

Omeros Corporation today announced the initiation of the planned pharmacokinetic (PK) substudy in its Phase 3 clinical program evaluating OMS302 in patients undergoing intraocular lens replacement (ILR) surgery.

1 Jun 2012

Ketamine reduces suicidal thoughts in patients with bipolar depression

Bipolar disorder is a serious and debilitating condition where individuals experience severe swings in mood between mania and depression. The episodes of low or elevated mood can last days or months, and the risk of suicide is high. Antidepressants are commonly prescribed to treat or prevent the depressive episodes, but they are not universally effective. Many patients still continue to experience periods of depression even while being treated, and many patients must try several different types of antidepressants before finding one that works for them.

31 May 2012

Taiho to initiate TAS-102 Phase III trial in colorectal cancer

Taiho Pharmaceutical Co., Ltd. announced on May 31 that a global Phase III clinical trial (RECOURSE) for the novel combination antimetabolite TAS-102 will start in June this year.

31 May 2012

Top-line data from Flexion‘s FX005 Phase 2 trial on osteoarthritis

Flexion Therapeutics, Inc. today reported that its lead osteoarthritis drug candidate, FX005, demonstrated significant pain relief over placebo at four weeks in a Phase 2 proof-of-concept trial. Top-line data showed FX005, delivered intra-articularly to the knee, was well-tolerated and resulted in prolonged improvement in joint pain and function throughout the 12-week duration of the study.

31 May 2012

Stiefel to acquire WBI-1001 licensing rights from Welichem

Stiefel, a GSK company, and Welichem Biotech Inc., have entered into an agreement for the acquisition by Stiefel of exclusive development and commercialization rights to the novel anti-inflammatory agent, WBI-1001, in all territories in the world outside of China, Taiwan, Macao and Hong Kong.

31 May 2012

CTI announces results from PIX301 phase 3 trial of Pixuvri for NHL

Cell Therapeutics, Inc. today announced that results from its PIX301 phase 3 clinical trial of Pixuvri (pixantrone) have been published online in The Lancet Oncology.

31 May 2012

Wellmune minimizes risk of URTI among marathoners

Marathoners taking Wellmune WGP, a natural immune health ingredient, for four weeks experienced an average reduction of 40% in upper respiratory tract infection symptomatic days that commonly afflict long-distance runners, according to new clinical study results presented today at the American College of Sports Medicine 59th annual meeting.

31 May 2012

Top-line results from Alnylam’s ALN-RSV01 Phase IIb trial on RSV infection

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today top-line results from a Phase IIb trial with ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection in lung transplant patients.

31 May 2012

Topline results from Alkermes’ ALKS 37 phase 2b study on opioid-induced constipation

Alkermes plc today announced topline results from a phase 2b dose-ranging clinical study of ALKS 37 in the treatment of opioid-induced constipation. The multicenter, randomized, double-blind, placebo-controlled, repeat-dose study was designed to assess the safety, tolerability, pharmacokinetic profile and efficacy of ALKS 37 in approximately 150 patients.

31 May 2012

Exelixis commences cabozantinib phase 3 pivotal trial in mCRPC

Exelixis, Inc. today announced the initiation of COMET-1, a phase 3 pivotal trial of cabozantinib in men with metastatic castration-resistant prostate cancer.

31 May 2012

Corrected interim data from Vertex VX-809, KALYDECO combination Phase 2 study for CF

Vertex Pharmaceuticals Incorporated announced today a correction to the previously reported responder analysis, as well as additional data from, the recent interim analysis of an ongoing Phase 2 study of VX-809 and KALYDECO that showed significant improvements in lung function among adults with cystic fibrosis who have two copies of the most common mutation in the cystic fibrosis transmembrane conductance regulator gene, F508del.

30 May 2012

DMARD not superior to oral therapy in long-term treatment of patients with JIA

A retrospective analysis of methotrexate (MTX) safety data found that injection of this disease-modifying anti-rheumatic drug (DMARD) was not superior to oral therapy in long-term treatment of patients with juvenile idiopathic arthritis (JIA). Findings published in Arthritis Care & Research, a peer-reviewed journal of the American College of Rheumatology (ACR), suggest that with similar efficacy and tolerability the more comfortable oral approach may be more suitable to treat pediatric arthritis patients.

30 May 2012

CytRx INNO-206 doxorubicin conjugate shows anti-multiple myeloma effects

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that in animal and in vitro studies, its tumor-targeting doxorubicin conjugate INNO-206 showed anti-multiple myeloma effects and enhanced the anti-tumor effects of bortezomib, which is approved for the treatment of relapsed multiple myeloma.

30 May 2012

JTCC to present latest findings in blood-cancer research at ASCO annual meeting

Physicians and researchers at John Theurer Cancer Center at HackensackUMC, one of the nation's top 50 cancer centers, will present the latest findings in blood-cancer research at the 2012 American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 1-5. Their involvement in these studies is part of John Theurer Cancer Center's continued focus to bolster its research program.

30 May 2012

Positive results from RedHill’s RHB-103 bioequivalence trial on acute migraine

RedHill Biopharma Ltd., an emerging Israeli biopharmaceutical company focusing primarily on development of late clinical-stage (Phase II/III), patent protected, new formulations and combinations of existing drugs, announces positive results in a pivotal bioequivalence clinical trial with RHB-103, an oral thin-film formulation of Rizatriptan for the treatment of acute migraine.

30 May 2012

Marshall Edwards initiates ME-344 Phase I trial in solid tumors

Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that the first cohort of patients has been dosed in a Phase I clinical trial of ME-344, the Company's lead mitochondrial inhibitor drug candidate, in patients with refractory solid tumors.

30 May 2012

NAC may be an effective therapy for some features of autism

A specific antioxidant supplement may be an effective therapy for some features of autism, according to a pilot trial from the Stanford University School of Medicine and Lucile Packard Children's Hospital that involved 31 children with the disorder.

30 May 2012